Literature DB >> 27629124

Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay.

Jian Liu1,2, Chunye Chen1, Rui Zhu1, Xiangzhong Ye3, Jizong Jia3, Lianwei Yang1, Yongmei Wang1, Wei Wang1, Jianghui Ye1, Yimin Li3, Hua Zhu2, Qinjian Zhao1, Jun Zhang1, Tong Cheng4, Ningshao Xia1.   

Abstract

Varicella is a highly contagious disease caused by primary infection of Varicella zoster virus (VZV). Varicella can be severe or even lethal in susceptible adults, immunocompromised patients and neonates. Determination of the status of immunity to VZV is recommended for these high-risk populations. Furthermore, measurement of population immunity to VZV can help in developing proper varicella vaccination programmes. VZV glycoprotein E (gE) is an antigen that has been demonstrated to be a highly accurate indicator of VZV-specific immunity. In this study, recombinant gE (rgE) was used to establish a double antigen sandwich enzyme-linked immunosorbent assay (ELISA). The established sandwich ELISA showed high specificity and sensitivity in the detection of human sera, and it could detect VZV-specific antibodies at a concentration of 11.25 m IU/mL with a detection linearity interval of 11.25 to 360 m IU/mL (R 2 = 0.9985). The double gE antigen sandwich ELISA showed a sensitivity of 95.08 % and specificity of 100 % compared to the fluorescent-antibody-to-membrane-antigen (FAMA) test, and it showed a sensitivity of 100 % and a specificity of 94.74 % compared to a commercial neutralizing antibody detection kit. Thus, the established double antigen sandwich ELISA can be used as a sensitive and specific quantitative method to evaluate immunity to VZV.

Entities:  

Keywords:  Double antigen sandwich ELISA; Glycoprotein E; Serological evaluation; Varicella zoster virus

Mesh:

Substances:

Year:  2016        PMID: 27629124     DOI: 10.1007/s00253-016-7821-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  2 in total

1.  Development of a skin- and neuro-attenuated live vaccine for varicella.

Authors:  Wei Wang; Dequan Pan; Wenkun Fu; Xiangzhong Ye; Jinle Han; Lianwei Yang; Jizong Jia; Jian Liu; Rui Zhu; Yali Zhang; Che Liu; Jianghui Ye; Anca Selariu; Yuqiong Que; Qinjian Zhao; Ting Wu; Yimin Li; Jun Zhang; Tong Cheng; Hua Zhu; Ningshao Xia
Journal:  Nat Commun       Date:  2022-02-11       Impact factor: 17.694

2.  Development of an Indirect ELISA Kit for Rapid Detection of Varicella-Zoster Virus Antibody by Glycoprotein E.

Authors:  Yan Niu; Aiping Wang; Jingming Zhou; Hongliang Liu; Yumei Chen; Peiyang Ding; Yanhua Qi; Chao Liang; Xifang Zhu; Gaiping Zhang
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.